TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response
Authors
Keywords
Melanoma, p53, MDM2, Nutlin-3, RG7388, HDM201, Trametinib, Vemurafenib
Journal
Cancer Cell International
Volume 19, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-03-07
DOI
10.1186/s12935-019-0768-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
- (2018) Lukasz Skalniak et al. Cancers
- Census and evaluation of p53 target genes
- (2017) M Fischer ONCOGENE
- Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf−/−mouse model
- (2017) Emilie A. Chapeau et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dose- and regimen-finding phase I study of NVP-HDM201 in patients (pts) with TP53 wild-type (wt) advanced tumors
- (2016) D. Hyman et al. EUROPEAN JOURNAL OF CANCER
- TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation
- (2016) Catherine J. Drummond et al. Oncotarget
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma
- (2014) L Chen et al. BRITISH JOURNAL OF CANCER
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trametinib: First Global Approval
- (2013) Cameron J. M. Wright et al. DRUGS
- Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
- (2013) Qingjie Ding et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Comprehensive Survey of Ras Mutations in Cancer
- (2012) I. A. Prior et al. CANCER RESEARCH
- p53 mutations in cancer
- (2012) Patricia A. J. Muller et al. NATURE CELL BIOLOGY
- Vemurafenib: the first drug approved for BRAF-mutant cancer
- (2012) Gideon Bollag et al. NATURE REVIEWS DRUG DISCOVERY
- GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
- (2011) A. G. Gilmartin et al. CLINICAL CANCER RESEARCH
- Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
- (2011) M H Aziz et al. ONCOGENE
- Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells
- (2011) M Michaelis et al. Cell Death & Disease
- Cancer-associated p53 Tetramerization Domain Mutants
- (2010) Rui Kamada et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The p53 orchestra: Mdm2 and Mdmx set the tone
- (2010) Mark Wade et al. TRENDS IN CELL BIOLOGY
- Reversal of P-glycoprotein-Mediated Multidrug Resistance by the Murine Double Minute 2 Antagonist Nutlin-3
- (2009) M. Michaelis et al. CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started